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A B S T R A C T
Introduction: Clear cell renal cell carcinoma (ccRCC) is the most common type among renal cell carcinomas, and
anti-angiogenic treatment is currently first line therapy in metastatic ccRCC (mccRCC). Response rates and
duration of response show considerable variation, and adverse events have major influence on patient's quality
of life. The need for predictive biomarkers to select those patients most likely to respond to receptor tyrosine
kinase inhibitors (rTKI) upfront is urgent. We investigated the predictive value of plasma interleukin-6 (pIL6),
interleukin-6 receptor α (pIL6Rα) and interleukin 6 signal transducer (pIL6ST) in mccRCC patients treated with
sunitinib.
Material and methods: Forty-six patients with metastatic or non-resectable ccRCC treated with sunitinib were
included. Full blood samples were collected at baseline before start of sunitinib and after every second cycle of
treatment during the study time. pIL6, pIL6R and pIL6ST at baseline and week 12 samples were analysed by
ELISA. The predictive potential of the candidate markers was assessed by correlation with response rates
(RECIST). In addition, progression free survival (PFS) and overall survival (OS) were analysed.
Results: Low pIL6 at baseline was significantly associated with improved response to sunitinib (Fisher's exact
test, p < 0.01). Furthermore, low pIL6 at baseline was significantly associated with improved PFS (log rank,
p=0.04). In addition, patients with a decrease in concentration of pIL6R between baseline and week 12 showed
significantly improved PFS (log rank, p=0.04) and patients with high pIL6ST at baseline showed significantly
improved OS (log rank, p=0.03).
Conclusion: Low pIL6 at baseline in mccRCC patients treated with sunitinib predicts improved treatment re-
sponse, and might represent a candidate predictive marker.
Introduction
Renal cell carcinoma (RCC) is the 7th most common cancer type
among men and 10th most common among women worldwide [1].
70–85% of RCC are clear cell RCC (ccRCC). After anti-angiogenic re-
ceptor tyrosine kinase inhibitors (rTKIs) showed superior efficacy over
interferon and interleukin-2 therapy, currently rTKIs are first line
treatment option for ccRCC [2]. Due to the diversity of treatment re-
sponse and toxicity among patients, the research community in-
vestigates potential predictive markers of response to antiangiogenic
treatment.
Vascular endothelial growth factor (VEGF) is the most important
mediator of tumour-associated angiogenesis in renal cell carcinoma [2].
In addition, some reports suggest a role of systemic inflammation in
development and progression of RCC [3–5]. Along with a stimulating
effect on tumour associated angiogenesis, VEGF also plays an important
role in the local immune response during wound healing as well as in
tumours by inducing accumulation of immature dendritic cells, mye-
loid-derived suppressor cells, regulatory T cells, and VEGF inhibits the
migration of T lymphocytes to the tumour [6].
Inflammation is one of the hallmarks of cancer, involved in devel-
opment and maintenance of cancer [7]. In a recent study, we found a
significant correlation between low serum C-reactive protein (CRP) and
objective response (OR) in mccRCC patients treated with sunitinib [8].
CRP is regarded a relevant biomarker for systemic inflammation [9].
Interleukin-6 (IL6) has a role in inflammation, infection responses and
the regulation of metabolic, regenerative and neural processes [10–13].
Tissue and serum levels of IL6 are elevated in RCC and secreted when
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cells are exposed to hypoxia. Enhanced level of IL6 results in RCC cell
invasion [10,14]. IL6 is also shown to be closely related to hypoxia-
inducible factor 1- α (HIF-1α) as well as increased VEGF activity [15].
The prognostic information of IL6 and IL6-receptor (IL6R) is well
known [10,16]. A predictive value of IL6 levels has also been reported
for response to immune checkpoint inhibitors [17]. IL6 signals in cells
via classic (membrane-bound) and trans-signalling (soluble) pathways
[18,19]. The interleukin 6 receptor α (IL6Rα) binds to the interleukin 6
signal transducer (IL6ST), also known as glycoprotein 130 (gp130)
protein receptor to transduce the signal. In a recent study, we identified
ccRCC tumour cell expression of IL6Rα as a predictive marker of re-
sponse to sunitinib treatment [20]. The membrane-bound IL6Rα is
found on hepatocytes and different leukocytes [21]. In trans-signalling,
soluble IL6 binds to soluble IL6R and the complex binds to cells ex-
pressing IL6ST [22]. Soluble IL6ST is also detected in the blood and has
been shown as an inhibitor of IL6 trans-signalling [23].
In the present work, we investigated the predictive and prognostic




Between 2007 and 2015, forty-six patients with radiologically
confirmed progressive mccRCC were enrolled in an open-label, single-
arm phase II study at Haukeland University Hospital, Norway.
Treatment was given as sunitinib 50mg/day on schedule four weeks
on/ two weeks off until disease progression, significant toxicity or
consent withdrawal. The study has previously been reported elsewhere
[8,24]. In summary, we observed 1 complete response (CR), 7 partial
responses (PR) and 18 patients with stable disease (SD) ≥ 6 months.
Twelve patients showed progressive disease (PD). Eight patients
stopped treatment before week 12 and were recorded as non-evaluable
for response rates and PFS. In response analyses objective response
(OR) is CR and PR together versus SD and PD and clinical benefit (CB) is
CR, PR and SD together versus PD. Clinical information is provided in
Table 1.
Ethics
The study was conducted in accordance with the ethical principles
of the Declaration of Helsinki and the International Conference on
Harmonization of Good Clinical Practice. The protocol was approved by
the Regional Ethics Committee (REK number 080/07 and REK number
78/05) and the Norwegian Medicines Agency. All participating patients
provided signed informed consent before enrolment.
Blood samples
Full blood samples were collected at baseline before start of suni-
tinib and after every second cycle of treatment during the study time.
After centrifugation, Na-heparin plasma samples were stored frozen at
−80 °C. For ELISA we used the heparin plasma sample tubes, which
was de-frozen in room temperature, shaken and then centrifuged for
different amount of fibrin precipitation.
Enzyme-linked immunosorbent assay (ELISA)
The antibodies used were human IL6 (P05231), human IL6R
(BMS214) and human IL6ST (EHIL6ST). Invitrogen, Thermo Fisher
Scientific, Waltham, MA, USA provided all three. For IL6 we used a
ready-to-use self-coating system kit (Invitrogen) and an ELISA 96-well
flat-bottom plate (Nune MaxiSorp flat-bottom (catalog number
44–2404), Invitrogen). For IL6R we used a ready-to-use sandwich ELISA
96 micro well plate coated kit with human IL6R (Invitrogen). For IL6ST
we used a ready-to-use self-coating system kit (Invitrogen). Phosphate
buffered saline (PBS); containing 0.05% (v/v) Tween 20 (PBS-T)
(Prod.nr. 822,184, Merck, USA) was used as washing buffer. All other
buffers used were from the respective ELISA kit. The staining process
was performed according to the manufactures manual and was analysed
at 450 nm with a microplate reader (Molecular Devices Emax).
Evaluation of ELISA results
We evaluated the ELISA results in according to the manufactures
manual. SoftMax Pro was used to evaluate the ELISA data and then
transferred to SPSS for statistical analysis. We categorized the baseline
ELISA variables (pIL6, pIL6R, pIL6ST), into low (below median) versus
high (above median). The change in pIL6, pIL6R and pIL6ST con-
centration between baseline and week 12 were divided into three ca-
tegories (decrease, stable, increase). We tested the decrease group
versus the stable and increase groups. The variables referred in the
paper are baseline values if not otherwise specified.
Tumour tissue samples and data
Immunohistochemically tumour tissue expression of interleukin-6
receptor α (IL6Rα), interleukin-6 (IL6), jagged1 (JAG1), vascular en-
dothelial growth factor A (VEGF-A), vascular endothelial growth factor
2 (VEGFR2), platelet-derived growth factor receptor β (PDGFRβ) and
heat shock protein 27 (HSP27) are previously published [24].
Statistical analyses
Comparisons between categorical variables were performed by
using the Fisher's exact test and Pearson chi-square. The Mann–Whitney
U test was used to compare the distribution of continuous variables
between two groups such as responders and non-responders. Logistic
regression analysis was used to test the relative importance of pre-
dictive factors for sunitinib response. Sample size calculations (alpha
0.05/ power 80%) indicated that 20 patients per group based on can-
didate marker expression were needed to detect a difference between
10% and 50% of patients having a response to treatment with sunitinib.
Kaplan–Meier estimates were constructed for time-to-event endpoints
such as PFS and OS, and log rank-test was applied for testing of dif-
ferences between groups. All p-values are two-sided. Statistical in-
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Forty-five of 46 (98%) cases had heparin plasma available for
quantification of pIL6 at baseline. Median value was 6.90 pg/ml (range
0.9–36.5 pg/ml). Twenty-six of 46 (56%) cases had heparin plasma
available for quantification of pIL6 at week 12. Median value was
8.90 pg/ml (range 1.0–18.8 pg/ml). Low baseline pIL6 was significantly
associated with clinical benefit (CB) (Fisher's exact test, p = <0.01)
(Table 2). Similarly, the continuous values of pIL6 was significantly
associated with CB (Mann–Whitney U test, p = <0.01) (Table 2). Lo-
gistic regression analysis was used to test the relative importance of the
following candidate predictive factors for clinical benefit to sunitinib;
International Metastatic Renal Cell Carcinoma Database Consortium
(IMDC) risk groups, baseline CRP, baseline European Organization for
Research and Treatment of Cancer Quality of Life (EORTC QoL)
symptom scale and pIL6. Of these, pIL6 was the only significant pre-
dictive factor for CB in the final model, with an odds ratio of 23.4
(p=<0.01). Low pIL6 was significantly associated with improved PFS
(median 14.7 months vs 5.3 months, log rank, p=0.04) (Table 3). Low
pIL6 was not significantly associated with OS (Tables 2 and 3).
Low pIL6 was significantly associated with normal CRP (Pearson
chi-square, p=0.05), but not with tumour tissue expression of IL6 or
IL6Rα (Supplementary Table 1).
pIL6R
Forty-six of 46 (100.0%) cases had significant heparin plasma for
quantification of pIL6R at baseline. Median value was 190.40 ng/ml
(range 115.0–288.9 ng/ml). Twenty-eight of 46 (60.9%) cases had
significant heparin plasma for quantification of pIL6R at week 12.
Median value was 164.13 ng/ml (range 94.7–248.4 ng/ml). pIL6R was
not significantly associated with CB (Table 2). Low pIL6R tended to be
associated with improved OS (median 26.3 months vs 13.7 months, log
rank, p=0.06) and not with PFS (Table 3).
Low pIL6R at baseline was significantly associated with age under
median (Pearson chi-square, p=0.04)). pIL6R was not significantly
associated with s-CRP or tumour tissue expression of IL6 or IL6Rα
(Supplementary Table 2).
pIL6ST
Forty-five of 46 (98.0%) cases had significant heparin plasma for
quantification of pIL6ST at baseline. Median value was 170.94 ng/ml
(range 102.2–260.84 ng/ml). Twenty-nine of 46 (63.0%) cases had
significant heparin plasma for quantification of pIL6ST at week 12.
Median value was 161.84 ng/ml (range 120.58–291.84 ng/ml). pIL6ST
was not significantly associated with CB (Table 2). High pIL6ST was
significantly associated with improved OS (median 25.2 months vs 12.7
months, log rank, p=0.04) and tended to be associated with improved
PFS (median 12.9 months vs 8.4 months, log rank, p=0.06) (Table 3).
pIL6ST was not significantly associated with s-CRP or tumour tissue
expression of IL6 or IL6Rα (Supplementary Table 3).
Change in candidate biomarkers between baseline and week 12
Twenty-five of 46 (54.3%) cases had significant heparin plasma for
quantification of pIL6 from baseline and week 12. Median value of the
change in pIL6 between baseline and week 12 was 1.99 pg/ml (range:
−13.4 to +11.9 pg/ml). The change in pIL6 was not significantly as-
sociated with PFS or OS (Table 3).
Twenty-eight of 46 (60.9%) cases had significant heparin plasma for
quantification of change in pIL6R between baseline and week 12.
Median value of the change in pIL6R between baseline and week 12 was
−24.63 ng/ml (range −63.8 to 17.5 ng/ml). The cases with decrease
had significantly better PFS than cases with stable or increased change
of pIL6R between baseline and week 12 (median missing vs 8.7 months,
log rank, p=0.04). We found no association with OS (Table 3).
Twenty-nine of 46 (63.0%) cases had significant heparin plasma for
quantification of change in pIL6ST between baseline and week 12.
Median value of the change in pIL6ST between baseline and week 12
was −2.40 ng/ml (range −108.68 to 137.87 ng/ml). We found no as-
sociation with PFS or OS (Table 3).
Discussion
Recently, an inverse response relationship was reported for VEGF
inhibitor (VEGFi) treatment and immune checkpoint inhibitor treat-
ment according to IMDC risk groups [25], and new predictive bio-
markers are needed to further optimize treatment for individual pa-
tients. The ongoing search for biomarkers to optimize VEGFi treatment
in renal cell carcinomas has so far been unsuccessful in finding pre-
dictive biomarkers useful for clinical practice. In a previous paper, we
presented results suggesting a predictive role of CRP [8]. This might
indicate that the immunomodulating effect of anti VEGF therapy plays
an important role in treatment response in addition to the effect on
angiogenesis. In the follow-up investigation, we found that low tumour
cell expression of IL6Rα was significantly associated with improved
objective response to sunitinib and low tumour cell expression of IL6
was significantly associated with PFS and OS [24]. In our present work,
we investigated the plasma level of baseline IL6, IL6R and IL6ST in the
Table 2
Plasma biomarkers in relation to response.
Variable Best overall tumor response (RECIST ver. 1.1)
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CB PD p valueg
pIL6 baseline <0.01
Mean value 6.13 14.82
pIL6R baseline 0.59
Mean value 189.30 183.47
pIL6ST baseline 0.21
Mean value 179.43 158.63
a Clinical benefit (Complete+Partial response+ Stable disease).
b Progressive disease.
c Fisher's exact test.
d Plasma Interleukin 6.
e Plasma Interleukin 6 receptor.
f Plasma Interleukin 6 signal transducer.
g Mann-Withney U test.
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same cohort with established metastatic ccRCC. Low baseline level of
pIL6 was significantly associated with clinical benefit of sunitinib
treatment and improved PFS.
Tissue and serum levels of IL6 are elevated in RCC, and high levels
of IL6 have been associated with elevated CRP in RCC patients [26,27].
IL6 signals cells via membrane-bound (classic) and soluble (trans-sig-
nalling) pathways [18,19]. The trans-signalling pathway is considered
to be pro-inflammatory [28]. Elevated IL6 has been associated with
poor survival in renal cell carcinoma and resistance to TKI treatment
[29–32]. Tumour cells produce IL6 in response to cellular stress such as
hypoxia, and enhanced levels of IL6 is associated with increased tumour
cell invasion [10,14]. Kwon et al. found a stimulating effect of elevated
IL6 on endothelial cells, which might represent a resistance mechanism
to anti-VEGF therapy [33]. As a response to cellular stress, IL6 activa-
tion of the transcription factor STAT3 drives angiogenesis by inducing
expression of VEGF and fibroblast growth factor (bFGF) by tumour
cells, and thereby supports vascularization required for tumour growth
and metastasis [34,35]. Our results are in support of previous reports
indicating that high levels of inflammation-associated cytokines are
negative for the outcome of treatment [13]. Elevated levels of IL6
among patients with poor response was also found in a recent work of
Mizuno, investigating angiogenic, inflammatory and immunologic
markers of sunitinib treatment in 56 patients with metastatic RCC [31].
However, they did not include patients with poor IMDC prognostic
score. Our findings may therefore show that we can include this group
as well. Tran et al. found opposite results, where a significantly increase
in PFS in patients treated with another rTKI (pazopanib) versus pla-
cebo, in patients with high serum IL6 [36].
The baseline value of soluble IL6R in plasma was not significantly
associated with response variables in this study, though low pIL6R
tended to be associated with improved OS. In our previous paper, low
tumour cell expression of IL6Rα was beneficial for treatment response.
The prognostic value of IL6R expression have previously been pre-
sented, where Costes et al. found a significant association between IL6R
expression and OS in patients with primary RCC tumours [16]. The
complexity of membranous and soluble IL6R is well discussed in several
reviews [10,34,37].
Membranous IL6ST is ubiquitous expressed in human tissue [38].
IL6ST and IL6R form a buffer for pIL6 in the blood, and is purposed to
be a mechanism by which the organism protects itself from unspecific
overstimulation by IL6ST [37]. Soluble IL6ST is an inhibitor of IL6.
Even though the range of pIL6ST in our cohort was lower than a normal
cohort, the group with under median level of pIL6ST level had worse OS
(Table 3), in line with previous findings [29]. This may support the idea
of a well-functioning buffer to protect against unspecific over-
stimulation by IL6-trans-signaling [37].
The cases with sunitinib induced reduction of pIL6R after two
rounds of treatment had improved PFS. A reduction of pIL6R might be
supported by the theory that trans-signaling pathways mediates cancer
development [28,39]. Our results suggest that this might be used as a
marker of beneficial on-treatment response, and suggest a relation be-
tween IL6Rα in tumour cells and level of circulating pIL6R.
In addition to the lack of a control group, our study has some
weaknesses. First, the number of patients included is low and thereby
the study lacks the statistical power to detect minor differences in re-
sponse rates between groups based on the biomarkers under in-
vestigation. Thus, our findings should be validated in an independent
and larger cohort of patients. Still, our data strongly suggest that bio-
markers associated with tumour immune responses might be important
in patients treated with anti-VEGF therapy.
Conclusion
Low level of plasma IL6 provides significant predictive information
about response to sunitinib, and our data thereby suggest that up-reg-
ulation of IL6 might represent an important mechanism of resistance.
Baseline measurement of this biomarker might guide clinical decision
making in treatment of patients with mccRCC.
Clinical practice points
The anti-angiogenic receptor tyrosine kinase inhibitor sunitinib is
first line treatment in metastatic renal cell carcinoma. Today there are
no established predictive markers in clinical use. Inflammation is an
Table 3
Survival analyses according to pIL6, pIL6R and pIL6ST.
Variable PFSa OSb
Median 95% CIc p-valued Median 95% CI p-value
pIL6e baseline 0.04 0.11
Low 14.7 1.9–27.6 25.2 15.6–34.8
High 5.3 1.8–8.8 8.3 3.0–13.6
pIL6Rf baseline 0.12 0.06
Low 14.7 1.6–27.8 26.3 4.7–47.9
High 8.7 7.6–9.8 13.7 11.0–16.5
pIL6STg baseline 0.06 0.04
Low 8.4 3.0–13.8 12.7 8.3–17.2
High 12.9 5.9–20.0 25.2 15.7–34.7
Change in pIL6 between baseline and week 12 0.03 0.63
Decrease 8.4 0.5–16.2 25.2 9.5–40.9
Stable/Increase 17.0 9.0–25.0 19.7 03–39.2
Change in pIL6R between baseline and week 12 0.04 0.40
Decrease −h −h 26.0 24.3–27.6
Stable/Increase 8.7 7.4–9.9 17.5 7.2–27.7
Change in pIL6ST between baseline and week 12 0.30 0.95
Decrease 16.5 1.9–32.2 19.7 9.0–30.5
Stable/Increase 8.4 6.0–10.7 13.9 9.3–18.5
a Progression free survival.
b Overall survival.
c Confidence interval.
d Log rank test.
e Plasma interleukin 6.
f Plasma interleukin 6 receptor.
g Plasma interleukin 6 signal transducer.
h Median survival cannot be calculated, due to less than 50% censored.
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important part of cancer. In our study, we find that low level of inter-
leukin 6 in plasma may predict treatment response of sunitinib and
guide clinicians in making better treatment plans in renal cell carci-
noma. The results suggest that up-regulation of plasma IL6 might re-
present an important mechanism of resistance. If validated in in-
dependent patient cohorts, the biomarker can easily be implicated into
routine practice for a low cost using ELISA.
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MicroAbstract
Anti-angiogenic treatment is first line treatment in metastatic renal
cell carcinoma. There are presently no clinically useful predictive
markers. In this study, we evaluate markers of tumor immune responses
and angiogenesis. We find that low level of plasma interleukin-6 may
predict response to sunitinib treatment. These results might represent
an important mechanism of resistance.
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